Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326417 · ClinicalTrials.gov registry record · Phase 1
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT00326417 is a Phase 1 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 97 participants.
The verdict
NCT00326417, a Phase 1 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of the current study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia transplanted with marrow from HLA-compatible unrelated donors. Specifically, the study will determine whether the addition of fludarabine to the conditioning regimen previously described by Deeg et al. will permit a reduction in the CY dose, to a point where sustained hematopoietic engraftment and survival are maintained (or improved), while the frequency of major regimen-related toxicity (RRT) and early deaths is reduced.
Interventions
- DRUG Fludarabine
- DRUG Cyclophosphamide 50mg
- DRUG Cyclophosphamide 150mg
- DRUG Cyclophosphamide 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2006-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326417
The ClinicalTrials.gov registry entry for NCT00326417 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT00326417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00326417 about?
NCT00326417 is a clinical study titled "Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)". The purpose of the current study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia transplanted with marrow from HLA-compatible unrelated donors. Specifically, the study will determine whether the addition of fludarabine to the conditioning regimen pr...
What is the current status of trial NCT00326417?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2006-01. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00326417?
The interventions under investigation include: Fludarabine (DRUG), Cyclophosphamide 50mg (DRUG), Cyclophosphamide 150mg (DRUG), Cyclophosphamide 100mg (DRUG).
Who is sponsoring clinical trial NCT00326417?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.